The OTEZLA® international website

This site is intended for healthcare professionals outside the U.S.


Reduction in BASDAI score sustained at 3 years1

Woman holding a pot of flowers

aPALACE 1-3 pooled analysis. LOCF; includes patients randomized to OTEZLA 30 mg BID or placebo at baseline.

bData as observed; includes patients who were randomized to OTEZLA 30 mg BID at baseline and remained on treatment for 156 weeks.

cP = 0.0002 vs placebo.

dMCID for BASDAI = -1.1 point improvement.2

During the placebo-controlled period, at week 16, patients taking OTEZLA 30 mg BID achieved a greater mean decrease in BASDAI score vs patients taking placebo (-1.53 vs -0.91; P = 0.0173).1†

*Pooled patient data from PALACE 1-3; BASDAI score was an exploratory measure in the subset of patients with axial symptoms and a baseline BASDAI score of >4 (n=454); BASDAI mean scores at BL were 6.6 for OTEZLA 30 mg BID and 6.4 for placebo.


BASDAI, Bath Ankylosing Disease Activity Index; BID, twice daily; BL, baseline; LOCF, last observation carried forward; MCID, minimum clinically important difference; PALACE, Psoriatic Arthritis Long-Term Assessment of Clinical Efficacy.


  1. Mease PJ, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (156-week) improvements in BASDAI in psoriatic arthritis patients: pooled results from 3 phase III, randomized, controlled trials. Ann Rheum Dis. 2017;76 (suppl 2): Abstract FRI0512.
  2. Kviatkovsky MJ, Ramiro S, Landewé R, et al. The minimum clinically important improvement and patient-acceptable symptom state in the BASDAI and BASFI for patients with ankylosing spondylitis. J Rheumatol. 2016;43(9):1680-1686.
You are leaving the OTEZLA® (apremilast) website
Do you wish to leave this site?
OTEZLA International Websites
OTEZLA is approved in 54 countries*
  • United States

  • Canada

  • Australia

  • Israel

  • Switzerland

  • New Zealand

  • Austria

  • Belgium

  • Bulgaria

  • Croatia

  • Republic of Cyprus

  • Czech Republic

  • Denmark

  • Estonia

  • Finland

  • France

  • Germany

  • Greece

  • Hungary

  • Ireland

  • Italy

  • Latvia

  • Lithuania

  • Luxembourg

  • Malta

  • Netherlands

  • Poland

  • Portugal

  • Romania

  • Slovakia

  • Slovenia

  • Singapore

  • Spain

  • Sweden

  • United Kingdom

  • Norway

  • Iceland

  • Liechtenstein

  • Russia

  • Japan

  • Hong Kong

  • Kuwait

  • Taiwan

  • UAE

  • South Korea

  • Thailand

  • Lebanon

  • Qatar

  • Argentina

  • Mexico

  • Brazil

  • Malaysia

  • Oman

  • Saudi Arabia

On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).

Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.

For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.